JP2021514677A5 - - Google Patents
Info
- Publication number
- JP2021514677A5 JP2021514677A5 JP2020568943A JP2020568943A JP2021514677A5 JP 2021514677 A5 JP2021514677 A5 JP 2021514677A5 JP 2020568943 A JP2020568943 A JP 2020568943A JP 2020568943 A JP2020568943 A JP 2020568943A JP 2021514677 A5 JP2021514677 A5 JP 2021514677A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- domain
- cancer
- chimeric cytokine
- inducible chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024029998A JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637600P | 2018-03-02 | 2018-03-02 | |
| US62/637,600 | 2018-03-02 | ||
| PCT/US2019/020340 WO2019169290A1 (en) | 2018-03-02 | 2019-03-01 | Inducible chimeric cytokine receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024029998A Division JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514677A JP2021514677A (ja) | 2021-06-17 |
| JP2021514677A5 true JP2021514677A5 (enExample) | 2022-03-10 |
| JP7526101B2 JP7526101B2 (ja) | 2024-07-31 |
Family
ID=65952060
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568943A Active JP7526101B2 (ja) | 2018-03-02 | 2019-03-01 | 誘導性キメラサイトカイン受容体 |
| JP2024029998A Active JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024029998A Active JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12163169B2 (enExample) |
| EP (1) | EP3759132A1 (enExample) |
| JP (2) | JP7526101B2 (enExample) |
| KR (2) | KR20250123938A (enExample) |
| CN (1) | CN111819192A (enExample) |
| AR (1) | AR114273A1 (enExample) |
| AU (2) | AU2019227979B2 (enExample) |
| BR (1) | BR112020017734A2 (enExample) |
| CA (1) | CA3091681A1 (enExample) |
| IL (2) | IL276831B2 (enExample) |
| MX (2) | MX2020009051A (enExample) |
| SG (1) | SG11202007771VA (enExample) |
| TW (1) | TWI897846B (enExample) |
| WO (1) | WO2019169290A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| EP3433269B1 (en) | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| EP3749685A4 (en) | 2018-02-09 | 2021-12-22 | National University of Singapore | ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY |
| CN111819192A (zh) * | 2018-03-02 | 2020-10-23 | 艾洛基治疗公司 | 可诱导的嵌合细胞激素受体 |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| AU2020232216B2 (en) | 2019-03-01 | 2025-09-25 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| PE20211902A1 (es) * | 2019-03-01 | 2021-09-27 | Allogene Therapeutics Inc | Receptores de citocinas quimericos constitutivamente activos |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| US12528856B2 (en) | 2019-08-30 | 2026-01-20 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising TGF β binding domains |
| EP4041893A4 (en) * | 2019-10-08 | 2023-08-30 | Provincial Health Services Authority | CHEMERACY CYTOKINE RECEPTORS |
| KR20220141299A (ko) * | 2020-01-14 | 2022-10-19 | 신테카인, 인크. | Il2 오르토로그 및 사용 방법 |
| MX2022010340A (es) * | 2020-02-24 | 2022-09-19 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas. |
| EP4110355A1 (en) * | 2020-02-24 | 2023-01-04 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer |
| CN115427440A (zh) | 2020-02-25 | 2022-12-02 | 圭尔医疗有限公司 | 用于工程化细胞的嵌合受体 |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| JP2023535371A (ja) * | 2020-07-17 | 2023-08-17 | シミュレックス インコーポレイテッド | 免疫抑制シグナル伝達をリダイレクトするためのキメラＭｙＤ８８受容体ならびに関連する組成物および方法 |
| EP4267601A1 (en) * | 2020-12-23 | 2023-11-01 | Quell Therapeutics Limited | Inducible signalling protein |
| TW202246492A (zh) * | 2021-02-24 | 2022-12-01 | 中國大陸商杭州啟函生物科技有限公司 | 用於增強的免疫療法的系統和方法 |
| KR102829018B1 (ko) | 2021-03-03 | 2025-07-04 | 서울대학교산학협력단 | 키메릭 항원 수용체-대식 세포의 제조 방법 및 그 세포의 용도 |
| AU2022254143A1 (en) * | 2021-04-07 | 2023-11-23 | Provincial Health Services Authority | Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same |
| CN113512125B (zh) * | 2021-04-26 | 2024-01-19 | 北京双赢科创生物科技有限公司 | 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞 |
| KR20240021179A (ko) * | 2021-05-14 | 2024-02-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 폴리펩티드 및 사용 방법 |
| JPWO2023276395A1 (enExample) * | 2021-06-28 | 2023-01-05 | ||
| AU2022348588A1 (en) | 2021-09-17 | 2024-04-04 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| EP4453022A1 (en) | 2021-12-22 | 2024-10-30 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| EP4499680A1 (en) | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| AU2023297866A1 (en) * | 2022-06-28 | 2024-12-12 | Resolution Therapeutics Limited | Switch receptors and modified immune cells |
| EP4554972A1 (en) * | 2022-07-11 | 2025-05-21 | The Board of Trustees of the Leland Stanford Junior University | Tunable cytokine receptor signaling domains |
| CN114949000B (zh) * | 2022-08-02 | 2022-10-04 | 卡瑞济(北京)生命科技有限公司 | 麝香提取物及其增强car-t细胞疗效的应用 |
| CN117683139A (zh) * | 2022-09-09 | 2024-03-12 | 信达细胞制药(苏州)有限公司 | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 |
| GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
| WO2024133472A1 (en) | 2022-12-22 | 2024-06-27 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| CN120981484A (zh) | 2023-01-23 | 2025-11-18 | 汉诺威医学院 | 抗entpd3嵌合抗原受体 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| AU2024219048A1 (en) | 2023-02-07 | 2025-08-07 | Quell Therapeutics Limited | Culture method for treg cells |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| EP4680728A1 (en) | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN121532650A (zh) | 2023-06-20 | 2026-02-13 | 艾洛基治疗公司 | 工程化的细胞的检测方法 |
| CN121586727A (zh) | 2023-06-21 | 2026-02-27 | 圭尔医疗有限公司 | 组成型细胞因子受体 |
| KR20260033032A (ko) * | 2023-06-29 | 2026-03-10 | 디스패치 바이오테라퓨틱스, 인크. | 합성 시토카인 수용체 |
| CN121620529A (zh) * | 2023-07-31 | 2026-03-06 | 南京传奇生物科技有限公司 | 嵌合细胞因子受体及其使用方法 |
| WO2025064779A1 (en) * | 2023-09-20 | 2025-03-27 | University Of Southern California | Synthetic tgf-beta redirectors and uses thereof in chimeric antigen receptor-mediated cell therapy and others |
| WO2025076134A1 (en) * | 2023-10-03 | 2025-04-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nk cells or t cells expressing chimeric hematopoietic growth factor receptors and methods of use |
| AU2024372734A1 (en) | 2023-10-30 | 2026-04-16 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025096643A1 (en) * | 2023-11-01 | 2025-05-08 | Baylor College Of Medicine | Reverse fate receptors to enhance the efficacy of engineered t cells |
| WO2025111277A2 (en) * | 2023-11-20 | 2025-05-30 | Carisma Therapeutics Inc. | Compositions and methods relating to redirected soluble modulators |
| WO2026008994A1 (en) | 2024-07-04 | 2026-01-08 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| IL114825A0 (en) | 1994-08-04 | 1995-12-08 | Regeneron Pharma | Rtk/cytokine receptor chimeras |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| AU3668897A (en) * | 1996-07-17 | 1998-02-09 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| WO2007075899A2 (en) | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
| SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| CA2738031C (en) | 2008-09-22 | 2022-11-29 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| WO2011069004A1 (en) | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| CA2832569A1 (en) * | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| ES2791598T3 (es) | 2013-06-05 | 2020-11-05 | Bellicum Pharmaceuticals Inc | Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa |
| EP3087101B1 (en) * | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| BR112017007003A2 (pt) * | 2014-10-07 | 2017-12-19 | Cellectis | método para modulação de atividade de células imunes induzidas por car |
| HK1245827B (en) | 2014-12-15 | 2020-06-19 | Board Of Regents Of The University Of Texas System | Methods for controlled activation or elimination of therapeutic cells |
| BR112017013981A2 (pt) | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| WO2016127257A1 (en) | 2015-02-12 | 2016-08-18 | University Health Network | Chimeric antigen receptors |
| US10294304B2 (en) | 2015-04-13 | 2019-05-21 | Pfizer Inc. | Chimeric antigen receptors targeting B-cell maturation antigen |
| US20180318303A1 (en) | 2015-04-15 | 2018-11-08 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| GB201514875D0 (en) * | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201522097D0 (en) * | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| KR20230167769A (ko) | 2016-08-26 | 2023-12-11 | 베이롤 칼리지 오브 메드신 | 세포 치료요법을 위한 항상성 활성 사이토킨 수용체 |
| MA46862A (fr) | 2016-11-17 | 2019-09-25 | Bluebird Bio Inc | Convertisseur de signaux tgf béta |
| US20190358263A1 (en) | 2016-12-07 | 2019-11-28 | Oslo Universitetssykehus Hf | Compositions and Methods for Cell Therapy |
| GB201702617D0 (en) | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| KR102879522B1 (ko) | 2017-03-03 | 2025-11-04 | 엑수마 바이오테크, 코포레이션 | 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물 |
| EP3735460A4 (en) * | 2017-09-18 | 2021-08-11 | Exuma Biotech Corp. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY OF THE LATTER |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| CN111819192A (zh) | 2018-03-02 | 2020-10-23 | 艾洛基治疗公司 | 可诱导的嵌合细胞激素受体 |
| CA3102641A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| PE20211902A1 (es) | 2019-03-01 | 2021-09-27 | Allogene Therapeutics Inc | Receptores de citocinas quimericos constitutivamente activos |
| AU2020232216B2 (en) | 2019-03-01 | 2025-09-25 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
-
2019
- 2019-03-01 CN CN201980016890.6A patent/CN111819192A/zh active Pending
- 2019-03-01 SG SG11202007771VA patent/SG11202007771VA/en unknown
- 2019-03-01 JP JP2020568943A patent/JP7526101B2/ja active Active
- 2019-03-01 IL IL276831A patent/IL276831B2/en unknown
- 2019-03-01 AR ARP190100529A patent/AR114273A1/es unknown
- 2019-03-01 IL IL317065A patent/IL317065A/en unknown
- 2019-03-01 US US16/290,388 patent/US12163169B2/en active Active
- 2019-03-01 EP EP19713907.4A patent/EP3759132A1/en active Pending
- 2019-03-01 KR KR1020257025809A patent/KR20250123938A/ko active Pending
- 2019-03-01 WO PCT/US2019/020340 patent/WO2019169290A1/en not_active Ceased
- 2019-03-01 MX MX2020009051A patent/MX2020009051A/es unknown
- 2019-03-01 BR BR112020017734-2A patent/BR112020017734A2/pt unknown
- 2019-03-01 CA CA3091681A patent/CA3091681A1/en active Pending
- 2019-03-01 AU AU2019227979A patent/AU2019227979B2/en active Active
- 2019-03-01 KR KR1020207027009A patent/KR102842692B1/ko active Active
- 2019-03-04 TW TW108107136A patent/TWI897846B/zh active
-
2020
- 2020-08-31 MX MX2025009955A patent/MX2025009955A/es unknown
-
2024
- 2024-02-29 JP JP2024029998A patent/JP7793667B2/ja active Active
- 2024-10-16 US US18/917,035 patent/US20250333719A1/en active Pending
- 2024-12-04 AU AU2024278090A patent/AU2024278090A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514677A5 (enExample) | ||
| IL276831B1 (en) | Inducible chimeric cytokine receptors | |
| JP2024074801A5 (enExample) | ||
| JP7555625B2 (ja) | 治療用化合物及び方法 | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| TWI809130B (zh) | 嵌合跨膜蛋白及其用途 | |
| US20250043013A1 (en) | Nucleic acids encoding il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy | |
| EP3341410B1 (en) | Chimeric antigen receptors with integrated controllable functions | |
| CN114341193A (zh) | 包括tgfβ结合结构域的嵌合细胞因子受体 | |
| CN112955172A (zh) | 靶向cd19和cd20的双顺反子嵌合抗原受体及其用途 | |
| CA2973529A1 (en) | Cll1-specific multi-chain chimeric antigen receptor | |
| CN107428829A (zh) | 靶向g‑蛋白偶联受体的嵌合抗原受体及其用途 | |
| CN113811327A (zh) | MUC1平行CAR(pCAR)治疗剂 | |
| JP2025161810A (ja) | Ｉｌ－１スーパーファミリーのサイトカインの空間時間的に制限された活性が武装化された免疫応答性細胞 | |
| US12187776B2 (en) | Pooling signaling and costimulatory domains in B7H6 chimeric antigen receptor | |
| JP2023503840A5 (enExample) | ||
| JP2024511992A (ja) | ガンマデルタｔ細胞刺激 | |
| JP2021514188A (ja) | Ｆｏｘｐ３標的因子組成物と養子細胞療法のための使用方法 | |
| CA3144071A1 (en) | Chimeric protein expressing t-cells | |
| CN118108833A (zh) | 引入外源二硫键的tcr恒定区及其产品和应用 | |
| JP2025506515A5 (enExample) | ||
| WO2026030667A1 (en) | Chimeric antigen receptors targeting the gamma delta t cell receptor | |
| HK1262734A1 (en) | Therapeutic compounds and methods |